Hong Kong IPOs 2025: Market views, mega deals, emerging trends Hong Kong cemented its status as the world’s leading initial public offerings venue in 2025, marking a year of momentum, progress and transformation. By mid-December, the market had raised HKD274.6 billion (USD35.2 billion) from 106 new listings, with four of the world’s top 10 IPOs…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s an exciting week not only for biotech M&A, but also for my city (Chicago) as we gear up for our big game this Saturday. Going into JPM, it’s good to be a…
The recent opening of the Hong Kong-Shenzhen Innovation and Technology Park in the Hetao cooperation zone is a defining milestone in Hong Kong’s journey to become an international tech hub. Heralded by Chief Executive John Lee Ka-chiu as a pivotal moment for local innovation, this is more than just a new facility; it marks a…
Adlai Nortye (NASDAQ: ANL) entered an exclusive license agreement with ASK Pharm for its pan‑RAS (ON) inhibitor AN9025 in mainland China, Hong Kong and Macao on Dec 29, 2025. ASK Pharm gains rights to develop, manufacture, and commercialize AN9025 in the Licensed Territory while Adlai Nortye retains worldwide rights elsewhere. The deal…
Go back a decade and most Americans had never heard of Huawei. Today, the Chinese telecom giant is a symbol of how quickly China can dominate a strategic technology sector and in the process create new national security and market threats for U.S. government and industry. Democratic Senator Mark Warner of Virginia, the top Democrat…
Pentagon personnel could soon be told to participate in new training programs designed to prepare them for anticipated advancements in biotechnology and its convergence with other critical and emerging technologies, like quantum computing and AI. House lawmakers recently passed an amendment en bloc in their version of the fiscal 2026 National Defense Authorization Act that…
Last month, I joined a US think tank delegation to China, participating in a round table at a top university in Beijing. A remark by a leading professor of diplomacy struck me: “If China and the US can’t cooperate on health issues, they can’t cooperate on others.” His words underscore the dire state of bilateral…
NKGen Biotech (OTC: NKGN), a clinical-stage biotech company, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. CEO Paul Y. Song will discuss their investigational NK cell therapy, troculeucel, for neurodegenerative diseases. The presentation will take place…
The U.K. is under pressure to offer a better deal to global pharmaceutical firms, as a slew of pulled investments and stalled drug pricing talks loom over U.S. President Donald Trump’s state visit to Britain. Drug companies have been urging U.K. authorities to pay more for drugs and improve the competitive landscape ahead of a…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. The news coming out of D.C. never stops. We get into all of it below. Trump reportedly discussing crackdown on Chinese drugs The Trump administration is considering implementing severe restrictions on drugs from…